Tuesday, September 15, 2026

How ILLIT’s “I Got Your Back” Became a Gold Hit in Just 3 Days!

The group ILLIT has achieved consecutive Gold Disc certifications in Japan.

How SCL Science’s Digital Logistics Platform BIONECT is Revolutionizing the Cold Chain Industry

SCL Science showcased its next-gen bio-logistics platform at the Korea Cold Chain 2026, emphasizing advanced cold chain logistics for healthcare.

How South Korea Influenced International Food Additive Standards at CODEX 2026

South Korea's MFDS leads discussions on international food additive standards at CODEX, enhancing global cooperation and safety assessments.

Tag: development

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

YH42946: The Promising HER2 Targeted Oral Treatment Set to Transform Cancer Care in 2026

Yuhan Corporation will reveal early results of its oral HER2-targeted therapy candidate 'YH42946' in clinical trials by year-end.

Navigating FDA Challenges: How SK Biopharmaceuticals Plans to Move Forward with Opacalim

SK Biopharm will maintain its development and commercialization plans for epilepsy drug candidate Opacalim despite FDA's partial clinical hold.

GC Pharma Wins Approval for Phase 2 Trial of COVID-19 mRNA Vaccine

GC Pharma has received approval for a Phase 2 trial of its COVID-19 mRNA vaccine candidate GC4006A and plans to advance toward Phase 3 while expanding the platform into other disease areas.

SK Biopharm’s Epilepsy Drug Trial Partially Halted in U.S., New Enrollment Suspended

SK Biopharm's U.S. trials of epilepsy drug candidate opicopalim have been partially placed on hold by the FDA, temporarily stopping new enrollment while existing patients continue treatment.

Top 5 Promising Lung Cancer Treatments Revealed at WCLC 2026: What You Need to Know

The world's largest conference on lung cancer will be held in Seoul after 19 years, showcasing clinical results from local pharmaceutical firms.

Unlocking the Future: South Korea’s 2031 BCI Research Plan with 300 Primates

The government plans to secure 300 primates for brain-computer interface research by 2031, focusing on safety and performance validation.

SK Biopharm’s Bold Move: How MD Expertise is Shaping Global Drug Development in 2026

SK Biopharm is enhancing its global competitiveness in drug development by establishing a specialized R&D system for new drug candidates.

How Nota’s AI Model Optimization Will Revolutionize LG’s Humanoid Robots in 2026

AI model optimization firm Nota will optimize the Vision Language Action Model for LG Electronics' humanoid robots.

Hanmi Pharmaceutical to Present Phase 2 Clinical Results for Congenital Hyperinsulinism Treatment at European Conference

Hanmi Pharmaceutical will present Phase 2 data on its investigational treatment efpeglenatide (HM15136) for congenital hyperinsulinism at the 64th European Society for Paediatric Endocrinology meeting in France.

Pharos iBio and Kolon Pharmaceutical Expand Joint Development of Lung Cancer Drug

Pharos iBio and Kolon Pharmaceutical are stepping up development of PHI-701, a next-generation EGFR inhibitor targeting patients who have developed resistance to existing targeted lung cancer treatments.

SK Biopharmaceuticals Introduces 128 NVIDIA B200 GPUs, Accelerating AI-Driven Drug Discovery

SK Biopharmaceuticals has secured 128 NVIDIA B200 GPUs to build large-scale AI infrastructure, accelerate AI-driven drug discovery, strengthen TR-AX, and explore new AI-based research business models.

Samsung Display Unveils Game-Changing Low-Power OLED Technology for Laptops in 2026

Samsung Display is developing new low-power OLED technology for laptops, enhancing energy efficiency and performance.

SK Biopharmaceuticals’s Opakalim: Targeting U.S. Launch in 2029—How Effective Is It at Suppressing Seizures?

SK Biopharmaceuticals takes a significant step with its epilepsy drug candidate Opakalim (BHV-7000) as it addresses the Xcopri one-tool challenge.

SOT106: The Groundbreaking ADC Cancer Drug Fast-Tracked by FDA for Soft Tissue Sarcoma

LigaChem Biosciences' antibody-drug conjugate (ADC) cancer treatment candidate has received Fast Track designation from the FDA.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.